Is it Time to Transform our Treatment of Type 2 Diabetes? - European Medical Journal
×

Browse

Is it Time to Transform our Treatment of Type 2 Diabetes?

| Download as | PDF
Chairpeople:
Michael Nauck,1 Dídac Mauricio,2 Anthony Barnett3
Speakers:
Tina Vilsbøll,4 Samy Hadjadj,5 Peter Rossing,6 Edoardo Mannucci,7 Harald Darius,8 Chantal Mathieu9
Disclosure:

Speakers participating in this symposium received honorarium from Bristol-Myers Squibb.

Acknowledgements:

Writing assistance provided by Dr Jonathan Viney.

Support:

The publication of this article was funded by Bristol-Myers Squibb. The views and opinions expressed are those of the authors and not necessarily of Bristol-Myers Squibb.

Citation
EMJ Diabet. ;1[1]:22-29.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This meeting comprised two sessions: the morning session centred around glucagon-like peptide-1 receptor (GLP-1R) agonists and SGLT-2 inhibitors, a new class of glucose-lowering compounds, while the afternoon session focused on new results of cardiovascular safety studies with diabetes medications, with special attention to the SAVOR-TIMI trial of saxagliptin.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.